Author | Year | Country | Ethnicity | M/F | N | Age | Cancer type | TNM stage | Sample source | Methods | Endpoints | Median follow-up time | Hazard ratio |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schetter et al | 2008 | USA | Non-Asians | 66/18 | 84 | 65 | CRC | I-IV | Tissue | RT-PCR | OS | 68 | 2.20 (1.10–4.60) |
Ayerbes et al | 2011 | Spain | Non-Asians | 25/13 | 38 | 63 | GIC | I-IV | Tissue | RT-PCR | OS | 22 | 1.07 (1.00–1.13) |
Osawa et al | 2011 | Japan | Asians | 26/11 | 37 | 65 | GC | I-IV | Tissue | RT-PCR | OS | 38 | 1.20 (1.12–1.58) |
Kim et al | 2012 | Korea | Asians | 57/34 | 91 | 61 | GC | I-IV | Tissue | RT-PCR | OS | 46 | 1.19 (0.83–1.69) |
Wang et al | 2012 | China | Asians | 43/22 | 65 | 60 | GC | I-IV | Blood | RT-PCR | OS | 36 | 1.58 (1.10–2.25) |
Huang et al | 2014 | China | Asians | 52/30 | 82 | 60 | GC | I-IV | Blood | RT-PCR | OS | 20 | 1.08 (1.02–1.15) |
Chen et al | 2015 | China | Asians | NR | 580 | NR | CRC | I-IV | Tissue | RT-PCR | OS | NR | 1.88 (1.09–3.23) |
Cheng et al | 2016 | China | Asians | 264/280 | 544 | 65 | CRC | I-IV | Tissue | RT-PCR | OS | 110 | 8.22 (4.47–15.12) |
Yang et al | 2017 | China | Asians | 35/20 | 55 | 60 | GC | I-IV | Blood | RT-PCR | OS | 34 | 2.30 (1.60–3.32) |
Peng et al | 2018 | China | Asians | 179/154 | 333 | 59 | GC | I-III | Blood | RT-PCR | OS | 36 | 2.07 (1.36–3.15) |
Shao et al | 2018 | China | Asians | NR | NR | NR | GC | NR | Tissue | RT-PCR | OS | NR | 1.02 (1.01–1.03) |
Pesta et al. | 2019 | Czech | Non-Asians | 18/10 | 28 | NR | CRC | I-IV | Blood | RT-PCR | OS | 36 | 1.67 (1.07–2.60) |